Epigenetic mutations and cancer therapy Effectiven(EZH2)

Cancer arises as a consequence of accumulating genomic alterations, which affect primarily oncogenes and tumor suppressor genes (TSGs). This condition creates a particular landmark that can be exploited in therapy. Not surprisingly, many pharma companies launched programs aimed to inhibit the gain of function activities caused by oncogene mutation and/or amplification, and many of these inhibitors are currently in the clinics. The situation is not so simple in the case of TSGs, where a common loss of function precludes, in most cases, their actual use as therapeutic targets.